European Space Agency Awards Exobiosphere €200K Contract to Advance Space-Enabled Bioengineering

Luxembourg - Exobiosphere has been awarded a contract of €200K by the European Space Agency (ESA) under the open-competition challenge Bioengineering in the Space Environment to conduct a nine-month study assessing the technical and commercial foundations of space-based bioengineering services.

The project aims to evaluate how microgravity and low-Earth orbit platforms can enable new approaches in drug discovery, regenerative medicine, and advanced tissue engineering.

Building on its Orbital High-Throughput System (OHTS), Exobiosphere will assess how automated, miniaturized, and parallelized biological experiments in orbit can generate measurable scientific and commercial value for pharmaceutical and biotechnology partners.

The study will define priority biomedical use cases, evaluate system compatibility with existing and upcoming space platforms (including ISS and commercial stations like Vast’s Haven-1), and deliver a validated business case and roadmap toward a future demonstration mission under ESA’s Business Applications program.

“This study allows us to rigorously define where space-enabled bioengineering creates real differentiation for drug discovery and tissue engineering, and how to translate that into a scalable commercial service,” said Kyle Acierno, CEO of Exobiosphere.

Over nine months, the project will combine structured customer engagement, technical feasibility assessment, and commercial modelling to establish a viable implementation pathway. The activity will engage leading research and biotech organisations to ensure strong scientific and market alignment.  Guillaume Prigent, Business Development and Partnerships Officer at ESA, stated “This feasibility study is part of ESA’s ongoing effort to explore potential commercial applications of space assets. Through its Business Applications programme, ESA provides a framework for industry to assess opportunities enabled by microgravity environments.”

The study will run from February 2026 and will conclude with a comprehensive roadmap and recommendations for a follow-on demonstration mission.  This activity is carried out under a programme of, and funded by, the European Space Agency.  The views expressed in the materials arising from this activity reflect those of Exobiosphere and can in no way be taken to reflect the official opinion of the European Space Agency.